New Anthropic Board Member Signals Healthcare Push [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
The move, announced this week, adds to the greater emphasis that the AI firm known for Claude seems to be making in the healthcare sector. Having rolled out “Claude for healthcare,” a fundamental framework for Anthropic's entrance, and inking deals with the likes of Eli Lilly and Novo Nordisk, the company is definitely looking to get more involved in healthcare, for example, in drug discovery. Daniela Amodei, in a statement around Narasimhan's appointment, has noted his significant contribution on more than 35 novel medicines during his tenure, and it seems that his addition will be useful in making Claude a go-to for clinicians. But that's not the only change that Narasimhan's arrival will make. Board Politics and Anthropic's Unique Mission If you've never heard of Anthropic's Long-Term Benefit Trust (LTBT), this arm of the firm is supposed to be a counterweight to investors, a check and balance on unfettered development that doesn't align with the core mission of keeping AI
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Announces Partnership with OpenAI [Yahoo! Finance]Yahoo! Finance
- Hims & Hers (HIMS) Jumps 48% Ahead of Earnings [Yahoo! Finance]Yahoo! Finance
- Notable healthcare headlines for the week: J&J, Abbott and Organon in focus [Seeking Alpha]Seeking Alpha
- Novo GLP-1 drug shows less lean mass loss than rivals, study says [USA TODAY]USA TODAY
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/20/26 - Form 6-K
- 4/13/26 - Form 6-K
- 4/7/26 - Form 6-K
- NVO's page on the SEC website